Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Sep 25 - Sep 30
Trials are investigating obesity, overweight with weight-related conditions, type 2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease
Diabetes, Obesity and Metabolism (January 2026), TRIUMPH-1 is structured as a basket trial with nested obstructive-sleep-apnea and osteoarthritis protocols, generating data across multiple indications simultaneously
By indication , the type-2 diabetes mellitus segment dominated the market with a 58% share in 2025, due to the fact that it is the largest indication of GLP-1 treatments with an extensive number of patients that have been steadily increasing because of high levels of obesity and sedentary lifestyles
People new to GLP-1 agonists If retatrutide is your first exposure to any GLP-1 receptor agonist, start at the lowest practical dose
US$ 28.12
US$ 29.62
US$ 22.08
US$ 23.64
US$ 23.00
US$ 22.93
